Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Issue 12 (1st December 2002)

• Record Type: Journal Article
• Authors: Peene, I; Meheus, L; Veys, E M; De Keyser, F
• Is Part Of: Annals of the rheumatic diseases. Volume 61:Issue 12(2002)
• Page Start: 1090
• Page End: 1094
• Publication Date: 2002-12-01
• Subjects: SSA/Ro52 -- SSA/Ro60 -- SSB -- antinuclear antibodies; ANA, antinuclear antibodies -- BCIP, 5-bromo-4-chloro-3-indolyl phosphatase -- CLE, cutaneous lupus erythematosus -- DM, dermatomyositis -- ELISA, enzyme linked immunosorbent assay -- pSS, primary Sjögren's syndrome -- RA, rheumatoid arthritis -- Ro52, 52 kD protein -- Ro60, 60 kD protein -- Scl, scleroderma -- SLE, systemic lupus erythematosus -- SS, Sjögren's syndrome; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.61.12.1090
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: To determine the diagnostic distribution in a consecutive anti-SSA and/or anti-SSB positive population. Methods: A total of 15 937 serum samples from 10 550 consecutive patients were analysed for antinuclear antibodies (ANAs) on HEp-2 cells. Serum samples positive for ANAs were analysed by immunodiffusion and line immunoassay with recombinant SSA-Ro52, natural SSA-Ro60, and recombinant SSB. Results: Among ANA positive patients in whom clinical information was available, 181 consecutive patients with anti-SSA and/or anti-SSB antibodies were identified, Disease associations were systemic lupus erythematosus (SLE) (45.3%), primary Sjögren's syndrome (pSS) (14.4%), scleroderma (8.8%), RA (7.7%), cutaneous lupus (7.7%), and dermatomyositis (2.2%). The ratio of diagnoses differed according to the anti-SSA/anti-SSB serotype. Scleroderma and dermatomyositis were enriched among mono-Ro52 reactive serum samples (34.2% and 10.5% respectively). Single reactivity towards Ro60 or anti-Ro60 with anti-Ro52 predisposed for SLE (80.0% and 52.2% respectively). Triple reactivity towards Ro52, Ro60, and SSB was primarily linked with SLE (55.8%) followed by pSS (20.9%). Anti-SSA on immunodiffusion increased the chance for SLE (62.8%), whereas isolated anti-SSB reactivity on immunodiffusion was less indicative for SLE (14.3%) and predisposed more for cutaneous lupus (23.8%) and pSS (33.3%). Conclusion: The diagnostic range associated with anti-SSA or anti-SSB reactivity differs significantly according to the detailed serotype defined by line immunoassay and immunodiffusion.